H. pylori - Ace Infectious
Targeted Drug Development Against H. pylori
Services
Online Inquiry

Targeted Drug Development Against H. pylori

Ace Infectious focuses on H. pylori research and provides not only H. pylori vaccine development services but also H. pylori drug development services. We provide drug development services targeting drug targets related to the survival, colonization, pathogenesis, and drug resistance mechanisms of H. pylori. Some of these targets are related to multiple mechanisms of H. pylori and we offer drug development services targeting the most prominent mechanism of the target. If you need to develop H. pylori drugs for a specific target of H. pylori, we can provide you with professional drug development proposals and customized drug development services.

Targeted drug development against H. pylori - Ace InfectiousFig. 1 Targeted drug development against H. pylori - Ace Infectious.

What we provide for targeted drug development against H. pylori

Targeted drug development services that related to survival mechanisms of H. pylori

Drugs targeting the survival mechanism of H. pylori can kill H. pylori in the quickest way, thereby rapidly alleviating the symptoms caused by H. pylori and avoiding drug-resistant mutations of H. pylori. Ace Infectious provides drug development services targeting survival mechanisms of H. pylori, including pH homeostasis mechanism, protein synthesis mechanism, self-protection mechanism, and energy metabolism mechanism.

H. pylori drug development targeting the survival mechanisms of H. pylori - Ace InfectiousFig. 2 H. pylori drug development targeting the survival mechanisms of H. pylori - Ace Infectious.

Targeted drug development services that related to colonization mechanisms of H. pylori

The ability of H. pylori to express genes differentially depending on the gastric acid environment is an important reason for H. pylori colonization. We provide drug development services for this pH-responsive regulation system and we offer specialized drug development services targeting the key enzymes AsrS and AsrR. In addition, some adhesins of H. pylori contribute to the colonization of H. pylori, and we offer drug development services for these adhesins, including BabA, HopQ, OipA, AlpA, and SabA. Furthermore, evasion of host immunity is another important reason for H. pylori colonization. We provide drug development services targeting H. pylori immune evasion-related proteins, including VacA, gamma-glutamyl transpeptidase, and cholesterol glycosyl-transferase.

Targeted drug development services that related to the pathogenesis of H. pylori

Drugs targeting the pathogenesis of H. pylori can decrease the discomfort caused by H. pylori. We provide drug development services targeting the cag pathogenicity island and HtrA of H. pylori. In drug development targeting the cag pathogenicity island, we offer specific drug development services targeting CagA, CagE, Cagα, Cagβ, and CagL.

Targeted drug development services that related to the drug resistance of H. pylori

H. pylori drug resistance is associated with the H. pylori efflux pumps. We provide drug development services targeting H. pylori drug-related efflux pumps, including HP1181, HP1165, hefABC, cznABC, HP1184, and HP1082.

In addition, efflux pumps are associated with the balance of important metal ions, which affects the activity of many enzymes, so we provide drug development services for these pumps, such as HP1561.

Cooperate with us

Ace Infectious provides drug development services for specific targets of H. pylori. Our targeted drug development services give us more advantages in the development of refined molecules for the treatment of H. pylori and help customers efficiently develop H. pylori therapeutic drugs. If you require any additional information or if you would like to discuss specific queries regarding your upcoming H. pylori drug development project, please feel free to contact us. We are waiting to collaborate with you to achieve the development of H. pylori drugs.

※ All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.